TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04367532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam rolling
Description: Foam rolling performed on cuff muscles in 3 sets of 30 seconds per each muscle part in duration with a 15-second rest between sets. The first sets on the central part of the cuff muscles, the second on the medial and third on the lateral side of the cuff.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue flossing
Description: A standard cuff muscle bandaging technique on cuff muscle. After the application, each participant is asked to perform a 2 min ankle-exercise program.
Study: NCT01382420

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: adrenalectomy
Study: NCT04024748

Intervention type: DEVICE
Intervention: PET/CT imaging
Description: Subjects will be have a PET/CT scan with PCD-1000A following their scheduled routine PET/CT scan. There will be no additional administration of radiopharmaceutical for the study.
Study: NCT00009620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Description: 10 mg of phenobarbital per kilogram of body weight intravenously over a period of 20 to 40 minutes (maximal dose, 1000 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of normal sal
Study: NCT01886820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NAV4694
Study: NCT02069210

Intervention type: OTHER
Intervention: Blood transfusion
Description: Intraoperative blood transfusion
Study: NCT01247233

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Breast Irradiation + Boost or Hypofractionated irradiation
Description: Whole Breast Irradiation 50 Gy + Boost 16 Gy or Whole breast, either 40 Gy in 15 fractions in 3 weeks or 42.5 Gy in 16 fractions in 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Description: Tumor bed 40 Gy in 10 fractions, 2 fractions of 4 Gy per day in 5 to 7 days.
Study: NCT03299257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil treatment
Description: 30-day donepezil treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: donepezil treatment
Description: 30-day donepezil treatment
Study: NCT04143750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Vicagrel
Description: Take a suspension of 20 mg vicagrel ,containing about 120 μCi \[14C\]Vicagrel, in fasting within 5 minutes
Study: NCT02959450

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified consistency and volume diet
Description: Modified consistency diet, with a certain viscosity and controlled volume, which was designed from recommendations based on the review of different studies. A Chef and a Nutritionist developed and determined the viscosity of the menus with a Brookfield Viscometer (model RV). All the menus were prepared and evaluated at the Food Technology Department of this Institute to achieve the viscosity required with a food thickener. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP. The patient and/or their caregivers in the intervention group must attend to a training workshop to explain how to use the food thickener.
Study: NCT04112901

Intervention type: DEVICE
Intervention: Microprocessor-controlled knee joints
Description: Any type of microprocessor-controlled knee joints will be considered; this includes those controlling stance phase only (e.g. Compact C-Leg), swing phase only (e.g. Smart IP), both swing and stance phases (e.g. Reho knee), or power generating knees (e.g. POWER knee Ossur).

Intervention type: DEVICE
Intervention: Non-microprocessor-controlled knee joints
Description: Any non-microprocessor-controlled knee joints such as prosthesis incorporating hydraulic, polycentric, pneumatic mechanisms, friction or locked knees.
Study: NCT00388557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine + ketaconazole
Description: vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration
Study: NCT03421431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305 Dose 1
Description: Two tablets daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-305 Dose 2
Description: Two tablets daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets daily for 12 weeks
Study: NCT03764956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic Index Therapy (LGIT)
Description: Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only. For this purpose, various dietary menus will be provided to the parents.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Atkins Diet (MAD)
Description: Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio. For this purpose, various dietary menus will be provided to the parents.
Study: NCT02604433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Subjects will start with luspatercept at 1 mg/kg dose level.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Subcutaneous, every 21 days.
Study: NCT02019589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT02904434

Intervention type: OTHER
Intervention: Grapefruit Juice
Description: On day 1 of the study, subjects will receive their standard voriconazole dose with no grapefruit juice. On day 2 of the study, subjects will receive approximately 240mL of reconstituted grapefruit juice by mouth or via nasogastric tube 30 minutes prior to receiving a scheduled dose of voriconazole. Blood samples will be collected during the 12 hours following voriconazole dosing on both days of the study.
Study: NCT04255069

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 1 JKB-122
Description: A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose 2 JKB-122
Description: A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
Study: NCT04434443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: trunk exercise on unstable exercise
Description: Participants would receive exercises on unstable surface. Started from supine position, participants had abdominal drawer-in maneuver with soft foam under the pelvic. Lower trunk rotation, bridging and abdominal muscles isometric contraction exercises were also used in this exercise during supine position, with different unstable surfaces used. Including soft foam under the feet, then progressed to BOSU ball under the feet, then progressed to the a BOSU ball under the feet combined with pelvic on soft foam. During sitting, BOSU ball and Swiss ball were used as unstable surface. Pelvic anterior-posterior tilt, lateral tilting, rotation, lifting, and stepping with arm swing were used in this position.
Study: NCT02967354

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
Description: Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
Description: Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
Description: Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
Description: Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
Description: Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan
Study: NCT02025569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strain Counterstrain

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham strain counterstrain
Study: NCT01568437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP-Block
Description: Block needle will be inserted out-of-plane to the ultrasound beam, perpendicular to the skin surface, until the tip lies deep between the fascia of the transversus abdominis muscle and the internal oblique muscle. 30 ml of the study solution in each side will be injected at this location and should be observed to spread in an anterior-posterior direction between two muscles. Each patient will receive a total dose of 60 ml of 0.25% bupivacaine (150 mg) + 1:200,000 epinephrine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Managment
Description: For these group.no TAP block administration. just conventional management for post operative pain.
Study: NCT02590263

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation
Description: Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation
Description: Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered per label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered per label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered per label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-414
Description: ABT-414 will be administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-414
Description: ABT-414 will be administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-414
Description: ABT-414 will be administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-414
Description: ABT-414 will be administered by intravenous infusion
Study: NCT02725099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chewing Ticagrelor
Description: 180 mg Chewing Ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ticagrelor
Description: 180 mg oral Ticagrelor
Study: NCT04027322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 0.25 MG/ML Inhalant Solution
Description: Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo for the control group.
Study: NCT01128738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1358820
Description: Onabotulinum toxin type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04214301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI800
Description: BLI800 Bowel Preparation
Study: NCT01078675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin calcium
Description: 5 mg, oral, once daily, 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin calcium
Description: 10 mg, oral, once daily, 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin calcium
Description: 20 mg, oral, once daily, 24 months
Study: NCT02827253

Intervention type: DEVICE
Intervention: MRI
Description: MRI will be performed during interdialysis period in the haemodialysis group. MRI will be performed at the beginning of the study in predialysis group.

Intervention type: DEVICE
Intervention: MRI
Description: MRI will be performed during interdialysis period in the haemodialysis group. MRI will be performed at the beginning of the study in predialysis group.
Study: NCT01296035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.
Study: NCT01530022

Intervention type: DRUG
Group type: OTHER
Intervention: Lacosamide (LCM)
Description: LCM 300 mg:~LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.~Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period

Intervention type: DRUG
Group type: OTHER
Intervention: Lacosamide (LCM)
Description: LCM 300 mg:~LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.~Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period

Intervention type: DRUG
Group type: OTHER
Intervention: Carbamazepine Immediate Release (CBZ-IR)
Description: CBZ-IR 600 mg:~CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.~LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period.

Intervention type: DRUG
Group type: OTHER
Intervention: Carbamazepine Immediate Release (CBZ-IR)
Description: CBZ-IR 600 mg:~CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.~LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period.
Study: NCT02357381

Intervention type: DEVICE
Intervention: eNeura SpringTMS
Description: Single pulse magnetic stimulation for prevention and/or treatment of migraine headache with or without aura.
Study: NCT02652962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis200
Description: 3 capsules each containing 0.70 g

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis200
Description: 3 capsules each containing 0.70 g

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis200
Description: 3 capsules each containing 0.70 g

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis200
Description: 3 capsules each containing 0.70 g

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%
Study: NCT03898115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHG Education
Description: The CHG educational intervention will include educational outreach and audit and feedback implementation strategies
Study: NCT04351022

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-38
Description: Split intravenous infusion of CART-38 cells \[dose escalating infusion of (5-20)x10\^6 CART-38 cells/kg\].
Study: NCT02678013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Radiofrequency ablation(RFA)for small recurrent HCC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA+highly-purified CTL
Description: Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC
Study: NCT02170935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 capsule
Study: NCT03416998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: Phototherapy will be performed using clusters of 12 diodes (Table 1); four 905 nm diodes (mean power of 0.3125 mW and peak power of 12.5 W for each diode; 250 Hz), four 875 nm diodes (mean power of 17.5 mW for each diode) and four 640 nm diodes (mean power of 15 mW for each diode). The device manufactured by Multi Radiance Medical® (Solon, OH, USA) will be used due to its high quality, ample use in clinical practice and due to the fact that no national companies manufacture diode clusters with the characteristics required for the proposed project.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: phototherapy
Description: Phototherapy will be performed using clusters of 12 diodes (Table 1); four 905 nm diodes (mean power of 0.3125 mW and peak power of 12.5 W for each diode; 250 Hz), four 875 nm diodes (mean power of 17.5 mW for each diode) and four 640 nm diodes (mean power of 15 mW for each diode). The device manufactured by Multi Radiance Medical® (Solon, OH, USA) will be used due to its high quality, ample use in clinical practice and due to the fact that no national companies manufacture diode clusters with the characteristics required for the proposed project.
Study: NCT02838485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror
Description: The healthy hand will be mirrored and the amputated hand unseen by the subject while performing hand movements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery
Description: The subject will be asked to imagine performing hand movements.
Study: NCT04434443

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Upper limb range of motion exercise
Description: Upper limb range of motion exercise with trunk fully supported
Study: NCT03570099

Intervention type: DRUG
Intervention: Naloxone Nasal Spray
Description: Naloxone Nasal Spray will be distributed at the addiction centres.

Intervention type: OTHER
Intervention: Historical control cohort
Description: Historical data will be retrieved from quality registries.
Study: NCT00518102

Intervention type: DRUG
Intervention: REGRANEX (becaplermin)
Description: A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).

Intervention type: OTHER
Intervention: REGRANEX (becaplermin) comparators
Description: A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX \[becaplermin\]) but are similar in characteristics to patients in the REGRANEX \[becaplermin\] user cohort)
Study: NCT01419964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 01
Description: ACH24

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 02
Description: Placebo
Study: NCT04636684

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Proteomic analysis
Description: Proteomic analysis based on mass spectrometry on the sample of valve tissues.
Study: NCT04139798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV03
Description: 100% Perfluorohexyloctane
Study: NCT03612284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contact lens insertion solution
Description: This contact lens solution is being tested for safety and comfort and is not an intervention. Subjects will have their scleral contact lenses filled with the test saline in the examination room and applied to their eyes. They will be monitored for symptoms and will be examined. Six to 8 hours later or whenever their lens clouding typically occurs they will return for further assessment and dispensing of solution if acceptable. subjects will use the solution for 5-9 days and return for a follow-up appointment. At each visit, subjects will complete an OSDI questionnaire and a Current Symptoms questionnaire.
Study: NCT05386784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene plus cholecalciferol
Description: Rabone D ( Raloxifene 60mg + Cholecalciferol 800 IU ) 1 Capsule once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: D3 oral base drop, 4 drops once daily (800 IU)
Study: NCT00424866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FGF-1
Description: Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg~Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle: 0 µg/kg
Study: NCT00120406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® PTX™ Drug Eluting Vascular Stent
Description: Stenting of the Superfemoropopliteal Artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioplasty
Description: Angioplasty of the Superfemoropopliteal Artery